secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001558370-22-006719
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong
--------------------------------------------------------------------------------

- Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).
- Jakafi net product rev $544M (+17% YoY); full-year guidance raised to $2.33-$2.40B from $2.3-$2.4B.
- Opzelura >38,000 new patients in Q1; 146M lives covered; vitiligo sNDA under FDA review, PDUFA July 18.
- Pemazyre approved in China; ruxolitinib QD NDA on track H1 2022; positive CHMP opinion for ruxolitinib in GVHD.
- Cash, equivalents & securities $2.5B as of March 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/0001558370-22-006719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/incy-20220503x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-006719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer